Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Bomedemstat (MK-3543) in Prior Bomedemstat Trial Participants
2023-506996-89-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of bomedemstat in myeloproliferative disorder (MPD), sponsored by Merck & Co. Primary endpoints: Percentage of participants with one or more adverse events and Percentage of participants who discontinued study treatment due to an adverse event. Planned start Apr 2024; status: authorised.
02
Drugs
bomedemstat
03
Conditions
myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on 2023-506996-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506996-89-00.